COX-2 controversy: where are we and where do we go from here?
- Published in:
- Inflammopharmacology, 2005, v. 13, n. 4, p. 395, doi. 10.1163/156856005774415583
- By:
- Publication type:
- Article
Works matching IS 09254692 AND DT 2005 AND VI 13 AND IP 4
Results: 7
1
2
The use of NSAIDs in rheumatic disorders 2005: a global perspective.
- Published in:
- Inflammopharmacology, 2005, v. 13, n. 4, p. 343, doi. 10.1163/156856005774415565
- By:
- Publication type:
- Article
3
The murky waters of the coxibs: a review of the current state of play.
- Published in:
- Inflammopharmacology, 2005, v. 13, n. 4, p. 371, doi. 10.1163/156856005774415619
- By:
- Publication type:
- Article
4
Introduction — The coxib controversies.
- Published in:
- Inflammopharmacology, 2005, v. 13, n. 4, p. 331, doi. 10.1163/156856005774415628
- By:
- Publication type:
- Article
5
The murky world of the COX-2-selective agents.
- Published in:
- Inflammopharmacology, 2005, v. 13, n. 4, p. 381, doi. 10.1163/156856005774415592
- By:
- Publication type:
- Article
6
Coxibs and their aftermath: an (opinionated) commentary, based on some historical viewpoints.
- Published in:
- Inflammopharmacology, 2005, v. 13, n. 4, p. 403, doi. 10.1163/156856005774415600
- By:
- Publication type:
- Article
7
COX-2 inhibitors: a story of greed, deception and death.
- Published in:
- Inflammopharmacology, 2005, v. 13, n. 4, p. 419, doi. 10.1163/156856005774415574
- By:
- Publication type:
- Article